Beam Therapeutics Quarterly Balance Sheet
NASDAQ: BEAMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Beam Therapeutics financial position
As of Jun 30, 2026, Beam Therapeutics reported total assets of $1.39 billion, down 0.3% from a year earlier against total liabilities of $318.9 million. Shareholders' equity stood at $1.07 billion, or 77.0% of assets. The company held $219.8 million in cash and equivalents against $100.3 million of debt, a net cash position of $119.6 million.
The current ratio (current assets divided by current liabilities) was 14.57, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.09.
Summary generated from market data by MetaCap's automated system. Methodology
Beam Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 219.82M | 288.29M | 294.94M | 267.96M | 282.13M | 527.91M | 281.97M | 230.20M | 292.76M | 287.85M | 435.89M | 169.05M |
| Short-Term Investments | 933.10M | 923.36M | 950.27M | 807.01M | 868.21M | 692.04M | 568.77M | 695.55M | 715.40M | 806.71M | 753.98M | 846.41M |
| Total Current Assets | 1.18B | 1.27B | 1.27B | 1.10B | 1.18B | 1.25B | 878.15M | 945.53M | 1.03B | 1.12B | 1.21B | 1.04B |
| Property, Plant & Equipment | 97.61M | 101.25M | 104.50M | 108.29M | 108.82M | 109.57M | 111.41M | 113.50M | 117.47M | 120.92M | 124.96M | 127.52M |
| Total Assets | 1.39B | 1.48B | 1.48B | 1.31B | 1.39B | 1.47B | 1.10B | 1.17B | 1.26B | 1.36B | 1.46B | 1.29B |
| Accounts Payable | 13.10M | 12.29M | 10.23M | 9.54M | 10.56M | 7.70M | 3.87M | 3.81M | 4.43M | 2.79M | 1.62M | 3.18M |
| Total Current Liabilities | 80.88M | 74.56M | 96.94M | 182.56M | 174.13M | 141.55M | 182.07M | 166.24M | 177.33M | 187.22M | 205.56M | 220.37M |
| Long-Term Debt | 100.26M | 100.19M | — | — | — | — | — | — | — | — | — | — |
| Total Liabilities | 318.91M | 316.36M | 242.82M | 345.08M | 344.34M | 343.78M | 370.28M | 380.05M | 407.17M | 446.31M | 478.38M | 511.59M |
| Shareholders' Equity | 1.07B | 1.16B | 1.24B | 966.00M | 1.05B | 1.13B | 733.54M | 791.32M | 854.09M | 913.49M | 981.33M | 778.94M |
| Retained Earnings | -1.86B | -1.74B | -1.64B | -1.89B | -1.78B | -1.68B | -1.57B | -1.48B | -1.38B | -1.29B | -1.19B | -1.33B |
| Total Debt | 100.26M | 100.19M | — | — | — | — | — | — | — | — | — | — |
| Net Cash (Debt) | 1.05B | 1.11B | 1.25B | 1.07B | 1.15B | 1.22B | 850.74M | 925.76M | 1.01B | 1.09B | 1.19B | 1.02B |
| Shares Outstanding | 103.26M | 102.74M | 101.75M | 101.36M | 100.76M | 100.56M | 83.63M | 82.56M | 82.39M | 82.28M | 81.63M | 79.38M |
This table shows 12 quarterly periods of Beam Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 15 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow BEAM's reporting calendar. What is a balance sheet?